MHUAFOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Meihua International Medical Technologies Co., Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026
$6.50+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
31.0%−10.7 pts over 5 years
Operating margin
13.4%−12.9 pts over 5 years
Net margin
11.0%−10.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -36.2% | -15.8% | -7.1% | – | |
| Gross profit | -42.5% | -20.5% | -12.4% | – | |
| Operating income | -42.1% | -8.5% | -18.8% | – | |
| Net income | -37.5% | +2.8% | -18.7% | – | |
| EPS, diluted | -54.5% | -12.6% | -28.3% | – | |
| Free cash flow | -96.2% | – | -18.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 26.4% | 3.9% | |
| Return on assets | – | – | 3.4% | |
| Current ratio | – | 3.17 | 8.42 | |
| Interest coverage | – | 171.1× | 34.3× | |
| Inventory turnover | – | – | 27.4× | |
| Capex to revenue | – | 4.3% | 0.0% | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Meihua International Medical Technologies generated $26.70M from operations and spent $5.08M on capital expenditure, dividends and share buybacks. 96% of that went back into the business.
Generated
$26.70M
Used
$5.08M
Capital expenditure$4.88M96%Dividends$00%Share buybacks$200.00K4%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin11.0%
×Asset turnover0.31×
×Equity multiplier1.13×
=Return on equity, FY20253.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 11.0% | 0.31× | 1.13× | 3.9% |
| FY2024 | 11.2% | 0.54× | 1.17× | 7.1% |
| FY2023 | 12.0% | 0.58× | 1.18× | 8.2% |
| FY2022 | 6.0% | 0.69× | 1.22× | 5.1% |
| FY2021 | 20.1% | 0.86× | 1.26× | 21.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$6.78M
- Cash generatingOperating cash flow above zero$569.88K
- Return on assets improvedROA up on the prior year6.3% → 3.6%
- Earnings backed by cashOperating cash flow above net income$569.88K vs $6.78M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.26 → 8.42
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year34.36% → 31.01%
- More efficientAsset turnover rose0.56 → 0.33